Literature DB >> 17651639

[Clinical analysis of the rare causes of hemoptysis: a report of 4 cases].

Wei Gu1, Li-hua Sun, Su-rong Fang, Ji-yong Ma, Ai-ping Zhang, Liang Chen.   

Abstract

OBJECTIVE: To improve the diagnosis of hemoptysis caused by rare lung diseases.
METHODS: Four cases of hemoptysis caused by rare diseases which were diagnosed by angiography or operation were reported and related literature were reviewed.
RESULTS: The 4 cases of hemoptysis were caused by intercostal-to-pulmonary arterial fistula (IPAF), pulmonary hamartoma (PH), congenital unilateral absence of the left pulmonary artery (ALPA) and primary pulmonary hypertension (PPH). Bronchial arteriography and bronchial artery embolization were performed for IPAF. For PH, a benign tumor, the diagnosis was based on the history and radiography examination, and operation was the choice for therapy. ALPA was confirmed by radiography, if massive hemoptysis occurred, surgical intervention was the best choice. The diagnosis of PPH was firstly evaluated by chest film and echocardiogram, and the final diagnosis relied on right cardiac catheter examination.
CONCLUSIONS: Hemoptysis is a common symptom of respiratory diseases, including some rare cases which are easy to be misdiagnosed. The correct diagnosis and therapy rely on comprehensive thinking, careful history collection and reasonable examinations.

Entities:  

Mesh:

Year:  2007        PMID: 17651639

Source DB:  PubMed          Journal:  Zhonghua Jie He He Hu Xi Za Zhi        ISSN: 1001-0939


  2 in total

1.  Isolated unilateral absence of pulmonary artery in adulthood: a clinical analysis of 65 cases from a case series and systematic review.

Authors:  Ping Wang; Ling Yuan; Juhong Shi; Zuojun Xu
Journal:  J Thorac Dis       Date:  2017-12       Impact factor: 2.895

2.  Safety and efficacy of transcatheter embolization in patients with massive hemoptysis due to intercostal pulmonary venous shunts.

Authors:  Zhigang Fu; Yonghui Liang; Wengjiang Zhao; Jie Tian; Fei Cai; Xiaolin Zhang
Journal:  Radiol Med       Date:  2019-03-09       Impact factor: 3.469

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.